KFFWP php=8.0.26 uname=Linux cephas 6.1.0-18-amd64 #1 SMP PREEMPT_DYNAMIC Debian 6.1.76-1 (2024-02-01) x86_64 uid=1001 user=www df=passthru,exec,system,putenv,chroot,chgrp,chown,shell_exec,popen,proc_open,pcntl_exec,ini_alter,ini_restore,dl,openlog,syslog,readlink,symlink,popepassthru,pcntl_alarm,pcntl_fork,pcntl_waitpid,pcntl_wait,pcntl_wifexited,pcntl_wifstopped,pcntl_wifsignaled,pcntl_wifcontinued,pcntl_wexitstatus,pcntl_wtermsig,pcntl_wstopsig,pcntl_signal,pcntl_signal_dispatch,pcntl_get_last_error,pcntl_strerror,pcntl_sigprocmask,pcntl_sigwaitinfo,pcntl_sigtimedwait,pcntl_exec,pcntl_getpriority,pcntl_setpriority,imap_open,apache_setenv open_basedir= euid=1001 ready KFFMORE mail=yes mb_send_mail=yes ffi=no imagick=no sqlite=yes curl=yes pcntl=no writable_cron=no home=/home/ict,/home/www Array ( [name] => www [passwd] => x [uid] => 1001 [gid] => 1002 [gecos] => [dir] => /home/www [shell] => /sbin/nologin ) cap=Name: php-fpm Umask: 0022 State: R (running) Tgid: 2507978 Ngid: 0 Pid: 2507978 PPid: 621 TracerPid: 0 Uid: 1001 1001 1001 1001 Gid: 1002 1002 1002 1002 FDSize: 64 Groups: 1002 NStgid: 2507978 NSpid: 2507978 NSpgid: 621 NSsid: 621 VmPeak: 115796 kB VmSize: 105560 kB VmLck: 0 kB VmPin: 0 kB VmHWM: 53932 kB VmRSS: 45740 kB RssAnon: 30120 kB RssFile: 15612 kB RssShmem: 8 kB VmData: 31856 kB VmStk: 132 kB VmExe: 8576 kB VmLib: 16812 kB VmPTE: 200 kB VmSwap: 2876 kB HugetlbPages: 0 kB CoreDumping: 0 THP_enabled: 1 Threads: 1 SigQ: 0/7645 SigPnd: 0000000000000000 ShdPnd: 0000000000000000 SigBlk: 0000000000000000 SigIgn: 0000000000001000 SigCgt: 0000000004004a07 CapInh: 0000000000000000 CapPrm: 0000000000000000 CapEff: 0000000000000000 CapBnd: 000001ffffffffff CapAmb: 0000000000000000 NoNewPrivs: 0 Seccomp: 0 Seccomp_filters: 0 Speculation_Store_Bypass: vulnerable SpeculationIndirectBranch: always enabled Cpus_allowed: 3 Cpus_allowed_list: 0-1 Mems_allowed: 00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000000,00000001 Mems_allowed_list: 0 voluntary_ctxt_switches: 1631 nonvoluntary_ctxt_switches: 285 KFFREAD ready KFFSQL curl_code=404 err= n=146 wrote /tmp/.kffso.so n=146 EX Call to undefined method SQLite3::enableLoadExtension() l6sq=false l6id=false KFFWD fwd_write=false fwd_exists=false sh=100 mail=true idfile=false r00t=false homewww=.,.. Vacancy Laboratory Manager Untuk Systematic Tracking of At-Risk Medicines – STARmeds

HOTLINE : 081314099130 EMAIL : cephas@univpancasila.ac.id :

Home
About Us
Research Project
Publication
Media
- Event
- News
- Article
- Announcement
Contact Us

Center for Pharmaceutical Policy, Management, & Service Studies

Navigasi : Home / Announcement / Vacancy Laboratory Manager Untuk Systematic Tracking of At-Risk Medicines – STARmeds

Vacancy Laboratory Manager Untuk Systematic Tracking of At-Risk Medicines – STARmeds

05/2021

Kategori : Announcement

Author : Administrator

Vacancy Laboratory Manager Untuk Systematic Tracking of At-Risk Medicines – STARmeds

Host entity	:	Faculty of Pharmacy, Universitas Pancasila
Duty station	:	Jakarta
Time Requirement	:	Three days a week (60%)
Language Skills	:	Indonesian and English
Start date	:	1 May 2021
Deadline	:	9 April 2021

Protecting society from poor quality medicines is a formidable task for national medicine regulatory authorities, especially in a resource-limited setting such as in Indonesia. Although post-market surveillance is a routine activity for medicine regulators, each country has different method in performing this task. To date, there are no globally recognised methods for estimating the prevalence of substandard and falsified medicines in a country, or for assessing their impact on health or the economy. With support from the UK government’s National Institute for Health Research, the Faculty of Pharmacy at Universitas Pancasila (UP) will collaborate with Imperial College London and Erasmus School of Health Policy and Management (ESHPM) to pilot a sentinel surveillance system for medicine quality, and to develop methods for estimating the prevalence, health and economic impact of poor quality medicines.

The concept arose from earlier research into the factors that incentivise the production, trade or consumption of falsified or substandard medicines. Substandard and falsified medicines are not distributed evenly throughout the market. Instead, they cluster around specific risk factors, which differ for substandard and for falsified medicines. Examples of risks for substandard medicines include irrationally low price, or poor product stability combined with long distribution chain. Examples of risks for falsified medicines include demand for off-label use, or availability in the unregulated supply chain.

We plan to conduct sentinel surveillance for substandard and falsified medicines in a number of areas, and then use the resulting data as the basis for developing national estimates of the risk of substandard and falsified medicines nationwide. (The process is modelled on a similar process used to develop methods for the estimation of populations at risk for HIV, pioneered in Indonesia in 2002 and subsequently adopted as a global gold standard by the World Health Organisation.)

Sentinel surveillance will be conducted in up to 9 districts within 5 provinces in Indonesia. The sample collection will be conducted in collaboration and with guidance from Balai Besar POM (BBPOM), and/or Badan Pusat Statistik (BPS), and in close coordination with the local Dinas Kesehatan. The process will involve mystery shoppers who will visit selected health care facilities and pharmacies for high risk medicines purchasing.

The medicines obtained will then transported to Jakarta for a complete compendial test according to Indonesian Pharmacopeia standards (FI) or the United States Pharmacopeia (USP). The complete compendial test comprises of testing for solid preparations, testing for semi-solid and non-sterile liquid preparations, testing for contamination, testing for sterile products, determining levels of active substances, determining potential for antibiotics (note: if there are antibiotics among the tested products), identification of active substance type, and degradation testing. The identification of assay and type of active substance will be conducted using spectrophotometric method or other relevant method. To that end, we seek to involve a laboratory manager to supervise and manage the laboratory testing process throughout this study to support the estimation of prevalence of substandard and falsified medicines.

Scope of Work

The selected candidate is expected to provide the following work:

Develop detail laboratory testing work plan, protocol, and budget, along with epidemiologist and program manager
Manage laboratory logistics procurement (e.g. reference standard, equipment, etc.)
Coordinate with external labs (BPOM or other) as necessary
Management of records and lab documents (ISO Documents), including appropriate management of electronic reporting formats
Conduct data validation
Conduct data analysis
Prepare laboratory testing report
Support the prevalence of substandard and falsified medicines estimation (coordinate with researcher in epidemiology)
Attend regular meeting with other researchers within the study (under the estimation of substandard and falsified prevalence group)

Qualifications

Master degree, preferably in Analytical Chemistry/ Pharmacy/equivalent experience.
At least 5 years experience in working in the area laboratory
Familiar with chromatography and spectrophotometry analytical method
Able to prove certified trainings in laboratory
Has good communication, strategic thinking, management, and monitoring skills
Thorough and very well organized
Fluent in Indonesian language and has good command of spoken English

For interested candidates, please send your CV (with two names of referee and their phone number)
and cover letter to: qualitymedicines_nihr@univpancasila.ac.id, cc: yn.nugrahani@univpancasila.ac.id no later than 9 April 2021.